Eyebank Corneal Tissue Prep May Increase Infection Risk

Share this content:
Eyebank Corneal Tissue Prep May Increase Infection Risk
Eyebank Corneal Tissue Prep May Increase Infection Risk

FRIDAY, Sept. 29, 2017 (HealthDay News) -- Donor rim cultures are more likely to have detectable Candida growth in endothelial keratoplasty-processed eyes than for other uses, according to a study published online Sept. 28 in JAMA Ophthalmology.

Kimberly M. Brothers, Ph.D., from the University of Pittsburgh, and colleagues used data from the 2013 Eversight Eyebank Study follow-up database for 6,592 corneal transplants to determine whether eyebank-processed endothelial keratoplasty tissue is at higher risk of contamination than unprocessed tissue. To assess whether processing steps at room temperature were a potential risk factor for fungal growth, Candida albicans, Candida glabrata, and Candida parapsilosis endophthalmitis isolates were each inoculated into optisol-gentamicin and -streptomycin (GS) and subjected to two room temperature incubation regimens reflective of current corneal tissue-handling protocols.

The researchers found that donor rim culture results were three times more likely to be positive for fungi in endothelial keratoplasty-processed eyes (1.14 percent) compared with other uses (0.37 percent). Increased room temperature incubation of optisol-GS increased growth of Candida species over time. Adding caspofungin and voriconazole decreased growth of Candida in a species-dependent manner.

"Detectable Candida growth in donor rim cultures, associated with a higher rate of post-keratoplasty infection, is seen in endothelial keratoplasty tissue vs. other uses at the time of transplantation, likely owing in part to eyebank preparation processes extending the time of tissue warming. Reduced room temperature incubation and the addition of antifungal agents decreased growth of Candida species in optisol-GS and should be further explored to reduce the risk of infection," conclude the authors.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

WHO: Vaccine Hesitancy a Major Global Health Threat

WHO: Vaccine Hesitancy a Major Global Health Threat

Percentage of U.S. children 19 to 35 months who have not been vaccinated has quadrupled since 2001

FDA Down to 5 Weeks of Funding to Review New Drug Applications

FDA Down to 5 Weeks of Funding to ...

Agency cannot accept new fees or applications until the shutdown is over

FDA Approves First Generic Version of Epilepsy Drug Sabril

FDA Approves First Generic Version of Epilepsy Drug ...

Generic equivalents held to same vigorous manufacturing standards as brand-name drugs

is free, fast, and customized just for you!




Already a member?

Sign In Now »